Global High-throughput Screening Market Outlook, 2031

The global high-throughput screening industry covers the instruments, reagents, consumables, software and services used to rapidly test large numbers of chemical compounds, biological molecules, genetic perturbations or cells for activity against biological targets or in disease models. High-throughput screening, often abbreviated as HTS, uses robotics, liquid handling systems, miniaturised assay plates with 384 or 1,536 wells, sensitive detection instruments and data analysis software to run hundreds of thousands to millions of tests, and it is a foundation of early drug discovery, toxicology, functional genomics and chemical biology. Major suppliers include Thermo Fisher Scientific, Danaher through Molecular Devices, Beckman Coulter and Abcam, Revvity, formerly PerkinElmer's life sciences business, Agilent Technologies, Tecan, Hamilton, Bio-Rad, Merck KGaA, Corning, BMG Labtech, Beckman's Echo acoustic liquid handlers from Labcyte, Bio-Techne, Promega, Eurofins Discovery, Charles River Laboratories and Sartorius. Contract research organisations such as WuXi AppTec, Evotec, Pharmaron, Reaction Biology and BioAscent provide screening services, while pharmaceutical companies, biotechnology firms, academic screening centres and government programmes operate their own facilities. Newer approaches include high-content imaging, which captures detailed cellular images, CRISPR functional genomic screens, DNA-encoded library screening and screening in organoids and other complex human cell models.

High-throughput screening has evolved from simply testing large compound libraries against purified targets to more biologically relevant and data-rich approaches. Phenotypic and high-content screening, which measure effects on whole cells, organoids and tissue-like models, have grown alongside target-based screening, and AI tools are increasingly used to analyse images and prioritise hits. CRISPR screens allow researchers to switch off or activate every gene in the genome to find drug targets, and single-cell and multi-omic readouts add depth. Regulatory changes are encouraging human-relevant models: the FDA Modernization Act 2.0, signed in December 2022, removed the legal requirement for animal testing before human trials, and in April 2025 the FDA announced a roadmap to reduce animal testing using new approach methodologies such as organoids, organ-on-chip systems and computer models, which are often screened at high throughput. Industry consolidation has continued, including PerkinElmer's sale of its analytical business and the renaming of its life sciences business as Revvity in 2023, and Danaher's USD 5.7 billion acquisition of Abcam, completed in December 2023. Demand has been affected by biotechnology funding cycles, with weak funding in 2022 and 2023 reducing instrument purchases, and by US research funding cuts in 2025. Geopolitical tensions, including the BIOSECURE Act enacted in December 2025, are affecting the use of Chinese screening service providers.

Market Dynamics Market Drivers • Demand for Faster and More Efficient Drug DiscoveryPharmaceutical and biotechnology companies must find new drug candidates quickly and at lower cost as patent expiries approach and competition intensifies. High-throughput screening allows researchers to test large libraries and identify starting points for drug development within weeks. Automation increases reproducibility and reduces labour, and screening is expanding to new modalities, including targeted protein degraders, covalent inhibitors, peptides and RNA-targeting small molecules.
• Growth of Complex Cell Models and Functional GenomicsResearchers increasingly use human cell-based assays, induced pluripotent stem cell-derived cells, organoids and organ-on-chip systems that better mimic human disease than simple biochemical assays. CRISPR screens, single-cell analysis and high-content imaging generate rich data about gene and compound effects. Regulators' encouragement of new approach methodologies to reduce animal testing further supports investment in high-throughput screening of human-relevant models.

Market Challenges • High Capital Costs and Technical ComplexityFully automated screening systems, high-content imagers and compound management facilities require large investments and specialised staff to operate and maintain. Small and mid-sized companies and academic laboratories may lack the resources, relying instead on contract providers or shared facilities. Complex cell models are harder to scale and standardise than biochemical assays, and managing and analysing large datasets requires advanced informatics.
• False Positives, Translation Gaps and Funding CyclesScreening campaigns can produce many false positives and hits that fail to translate into effective drugs, and the correlation between screening results and clinical success is imperfect. Biotechnology funding downturns and reductions in government research funding, such as US NIH cuts in 2025, reduce spending on instruments and services. Supply chain disruptions and geopolitical restrictions on outsourcing add uncertainty.

Market Trends • AI-Driven Screening and Virtual ScreeningArtificial intelligence is used to design screening libraries, analyse high-content images, predict compound activity and prioritise hits, and virtual screening of ultra-large chemical libraries of billions of compounds can reduce the number of physical tests needed. AI and physical screening increasingly work together, with virtual screening narrowing candidates and experimental screening generating data to train models. Automated laboratories run closed-loop design, test and learn cycles.
• Miniaturisation, Organoids and New Approach MethodologiesScreening assays continue to shrink to 1,536-well plates and microfluidic formats to save reagents and increase throughput, and acoustic dispensing allows precise transfer of tiny volumes. Organoids, organ-on-chip systems and 3D cell cultures are being adapted to high-throughput formats, supported by companies such as Emulate, CN Bio and MIMETAS. Regulatory encouragement of alternatives to animal testing is increasing their use in efficacy and toxicology screening.



Segment Analysis Instruments account for a large share of high-throughput screening spending, while reagents, consumables and services generate recurring revenue and are growing faster. Instruments include liquid handling systems and robotic workstations from Hamilton, Tecan, Beckman Coulter and Agilent; acoustic dispensers; plate readers for absorbance, fluorescence, luminescence and other detection from Molecular Devices, BMG Labtech, Revvity and Thermo Fisher; high-content imaging systems; flow cytometers adapted for screening; automated incubators, plate handlers and integrated robotic systems; and mass spectrometry-based screening platforms. Instruments account for a large share of spending but are purchased periodically. Reagents and assay kits, including detection kits, cell lines, enzymes, antibodies and cell culture media, and consumables such as microplates, pipette tips and reservoirs from Corning, Greiner and Thermo Fisher, are purchased continuously and provide recurring revenue. Compound libraries, including diverse screening collections, fragment libraries and DNA-encoded libraries from suppliers such as Enamine and ChemDiv, are key inputs. Software and informatics, including laboratory information management systems, data analysis, image analysis and AI tools, manage and interpret screening data. Services, including assay development and screening campaigns performed by contract research organisations and academic core facilities, allow companies to access screening without owning equipment.

Cell-based assays account for the largest and fastest-growing share of high-throughput screening, while biochemical assays remain important for target-based discovery. Cell-based assays measure the effects of compounds or genetic perturbations on living cells, including cell viability, signalling pathways, reporter gene expression, ion channel activity and changes in cell shape, and they provide more physiologically relevant information than purified protein assays. They include assays in immortalised cell lines, primary cells, stem cell-derived cells, 3D cultures and organoids. High-content screening, which uses automated microscopy and image analysis to measure many features of cells, is a fast-growing type of cell-based screening. Biochemical assays test compounds against purified proteins, such as enzymes and receptors, using detection methods such as fluorescence, luminescence and time-resolved fluorescence, and they remain widely used for target-based discovery because they are simple and scalable. Label-free technologies, including surface plasmon resonance and mass spectrometry, detect binding without fluorescent tags. Functional genomic screens, including CRISPR knockout, activation and interference screens and RNA interference, identify genes involved in disease. Ultra-high-throughput screening, testing more than 100,000 samples a day, is used by large pharmaceutical companies. DNA-encoded library screening provides an alternative to plate-based testing for very large libraries.

Drug discovery is the largest application of high-throughput screening, while toxicology, functional genomics and biologics discovery are important and growing applications. Drug discovery, including target identification, hit discovery and lead optimisation for small molecules, is the largest application, used by pharmaceutical companies, biotechnology firms and contract research organisations to find starting points for new medicines. Target identification and validation use functional genomics screens to find genes that drive disease. Toxicology and safety screening use high-throughput assays, including stem cell-derived cardiomyocytes, hepatocytes and neurons, to identify compounds likely to cause toxicity early, and regulators' interest in new approach methodologies supports this application. Biologics discovery, including screening of antibody libraries, peptides and engineered proteins using display technologies and single-cell platforms, is growing. Stem cell research and regenerative medicine use screening to find compounds that direct cell differentiation. Academic research uses screening to discover chemical probes and understand biology, supported by national screening centres. Agrochemical discovery screens compounds for crop protection. Materials science and consumer product testing, including cosmetics safety testing without animals, are further applications. Drug repurposing screens test approved drugs against new diseases.

Pharmaceutical and biotechnology companies are the largest users of high-throughput screening, while contract research organisations and academic institutions form major customer groups. Pharmaceutical companies operate large screening facilities with extensive compound libraries and automation, and they account for the largest share of screening spending, although many have reduced internal capacity and outsourced part of the work. Biotechnology companies use screening for their discovery programmes, often through contract providers or collaborations, and their spending fluctuates with venture funding. Contract research organisations, including WuXi AppTec, Evotec, Charles River Laboratories, Pharmaron, Eurofins Discovery, Reaction Biology and BioAscent, provide screening services and are major buyers of instruments and consumables, with some customers diversifying providers because of US restrictions on certain Chinese companies. Academic and research institutes, including university screening cores, the US National Center for Advancing Translational Sciences and European infrastructures such as EU-OPENSCREEN, run screening programmes for academic researchers. Government and non-profit organisations screen for neglected diseases, pandemic preparedness and toxicology. Agrochemical, chemical and consumer product companies use screening for their products. AI drug discovery companies combine screening with machine learning in automated laboratories.

Regional Analysis North America leads the high-throughput screening market because of large pharmaceutical and biotechnology R&D spending, leading instrument suppliers and academic screening centres, while Asia-Pacific is the fastest-growing region. North America, led by the United States, accounts for the largest share of the high-throughput screening market. The United States has major pharmaceutical research centres, thousands of biotechnology companies, large academic and government screening facilities, and leading suppliers such as Thermo Fisher, Danaher, Agilent, Revvity, Corning and Bio-Rad. The FDA Modernization Act 2.0 and the FDA's 2025 roadmap to reduce animal testing have encouraged investment in human cell-based screening, while NIH funding cuts in 2025 and biotechnology funding cycles have affected demand. The BIOSECURE Act enacted in December 2025 is prompting some US companies to shift screening work away from Chinese providers. Canada has growing screening capabilities. Europe is the second largest region, with strong pharmaceutical research in Switzerland, the UK, Germany, Denmark and France, suppliers such as Tecan, Hamilton's European operations, BMG Labtech, Merck KGaA and Sartorius, contract providers such as Evotec, and the EU-OPENSCREEN research infrastructure. EU policies on reducing animal testing support new approach methodologies. Asia-Pacific is the fastest-growing region, with China's large contract research sector and growing biotechnology industry, Japan's established pharmaceutical research, and expanding capabilities in South Korea, India, Singapore and Australia. India's contract research organisations are growing as Western companies diversify away from China. Latin America, the Middle East and Africa have smaller markets, with research capacity growing in Brazil, Israel and the Gulf states.

Key Developments June 2026: The US Department of Defense added WuXi AppTec to its list of Chinese military companies, bringing it within the scope of BIOSECURE Act restrictions on federally funded work.
December 2025: The BIOSECURE Act, included in the Fiscal Year 2026 National Defense Authorization Act, restricted US federal agencies and contractors from using biotechnology equipment or services from designated companies of concern.
April 2025: The FDA announced plans to phase out animal testing requirements for some drugs in favour of new approach methodologies, including organoids, organ-on-chip systems and computational models.
December 2023: Danaher completed its USD 5.7 billion acquisition of Abcam, adding antibodies and assay reagents used in screening and research to its life sciences portfolio.
May 2023: Following the sale of its analytical instruments business, PerkinElmer's life sciences and diagnostics business was renamed Revvity, a major supplier of screening instruments and reagents.
December 2022: US law removed the requirement that drugs be tested in animals before human trials, allowing cell-based assays, organ chips and computer models to support applications.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global High-throughput Screening Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Product and Service
• Instruments
• Reagents and Assay Kits
• Consumables
• Compound Libraries
• Software and Informatics
• Services

By Technology
• Cell-Based Assays
• Biochemical Assays
• High-Content Screening
• Label-Free Technologies
• Functional Genomic Screening
• Ultra-High-Throughput Screening

By Application
• Drug Discovery
• Target Identification and Validation
• Toxicology and Safety Screening
• Biologics Discovery
• Academic Research

By End User
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organisations
• Academic and Research Institutes
• Government and Non-Profit Organisations